Chemotherapy-naive patients with non-small cell lung cancer (NSCLC) along with epidermal growth factor receptor mutations of the tyrosine kinase domain have greater responses to gefitinib than those who have received chemotherapy, according to Taiwanese researchers. Reuters Health Information
This chronic disorder is often viewed with skepticism and uncertainty, but a growing body of evidence offers keys to diagnosis and treatment. Medscape Pharmacists
In one of the first studies to examine use of COX-2 inhibitors after their association with increased cardiovascular risk became apparent, Swedish researchers find no increase in MI, stroke, or heart failure with use of these agents in a nationwide cohort. Heartwire
Long-term follow-up of patients with systemic necrotizing vasculitides refractory to standard treatment indicates that therapy with the tumor necrosis factor (TNF)-alpha blocker infliximab is safe and effective, according to French researchers. Reuters Health Information
